119 results
Page 5 of 6
6-K
EX-10.1
ecy4vqmw n8
12 May 20
Current report (foreign)
12:04pm
424B5
tjm51ubp1b mkbu
12 May 20
Prospectus supplement for primary offering
12:02pm
6-K
EX-99.1
tr41x87 udt713
11 May 20
VBL Therapeutics Announces $10.0 Million Registered Direct Offering
9:23am
6-K
EX-4.1
e9zfy89qx 4k9z9
11 May 20
VBL Therapeutics Announces $10.0 Million Registered Direct Offering
9:23am
6-K
EX-10.1
59r ea8v99
11 May 20
VBL Therapeutics Announces $10.0 Million Registered Direct Offering
9:23am
424B5
871mfjvkvcx82mx
11 May 20
Prospectus supplement for primary offering
9:23am
6-K
EX-99.1
og2ynwd fnpb6
26 Mar 20
VBL Therapeutics Announces Positive Outcome of the Interim Analysis in the OVAL Phase 3 Ovarian Cancer Pivotal Study
8:08am
6-K
EX-99.1
00ydn3
19 Mar 20
Current report (foreign)
7:25am
6-K
13ylkdinr2
14 Nov 19
Current report (foreign)
7:01am
6-K/A
tky2 7mu9v
29 Aug 19
Current report (foreign) (amended)
5:25pm
6-K
p3v6s478v1o90j5znka
13 Aug 19
Current report (foreign)
7:00am
424B5
tygc x1ge9dnav6
17 May 19
Prospectus supplement for primary offering
5:19pm
6-K
rp4gic3nq 0r4jdh
15 May 19
Current report (foreign)
7:00am
6-K
e1mbnahyvy5y
20 Nov 18
Current report (foreign)
7:00am
6-K
EX-99.1
0l3s2wyrpk30souz
16 Nov 18
Current report (foreign)
8:46am
6-K
EX-99.1
0kdw02fra13zxavkdf
23 Oct 18
Newly Granted European Composition of Matter Patent Extends Exclusive Protection for VBL Therapeutics’ Lead Drug Candidate VB-111 until October 2033
8:16am
6-K
slnimaebe ddhqr
16 Aug 18
Current report (foreign)
7:00am
424B5
ngr9tw
27 Jun 18
Prospectus supplement for primary offering
9:30am